Insulin Therapy Center

n this week's Homerun Slides, finding the common ground between - and possible path to treatment of - hyperglycemia and the causes of vascular disease.

In this week's Homerun Slides, a continued explanation of insulin resistance and its causes, as well as its impact on hyperinsulinemia.

In this week's Homerun Slides, the effects of hyperinsulinism.

When it comes to antidiabetic therapies, professionals should be aware of safety concerns with concentrated insulin formulations, metformin and renal function, and SGLT-2 inhibitors and DKA. See the breakdown of these safety issues by Tom Palma, RPh, MS, BCPS, and Greg Wiggers, PharmD, PhD, plus exclusive commentary by DIC Advisory Board member Dr. George Bakris.

Female, 26 years of age, type 1 diabetes for 15 years, well-educated, uses insulin pump. Recent A1C 7.6%; has been rising from 6 to 6.5. Thinks her mealtime insulin is not working fast enough. She does bolus about 20 minutes before eating. Assessed pump, CGM, food intake and activity. Her report seemed to be the case.

Dr. Stanley Schwartz asks and begins to answer the question: is insulin beneficial for the vasculature as well as the patient -- or not?

Only GLP-1 receptor agonist for use with mealtime or basal insulin for adults with type 2.

Early initiation of therapy hoped to reduce long-term morbidity, mortality by getting to goal earlier; potentially alter the natural history of the disease.

Dr. Israel Hodish talks with Diabetes in Control Publisher Steve Freed at the 2016 ADA Meeting about his ADA presentation on the outcome of patients using insulin and why insulin therapy doesn't work.

Investigation supports that early diabetes has lower thromboembolic risk than later.